Eisai's novel antiepileptic drug Fycompa (perampanel) has been approved by the US FDA after a bumpy regulatory ride, for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in epilepsy patients aged 12 or older.
The first-in-class, oral non-competitive AMPA-type glutamate receptor antagonist was approved by the European Commission in July for the same indication, and has already been
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?